Valeant Pharmaceuticals Intl Inc (VRX) Receives Consensus Recommendation of “Hold” from Brokerages
Shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) have been given a consensus recommendation of “Hold” by the five ratings firms that are covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is C$23.33.
VRX has been the subject of several analyst reports. Royal Bank Of Canada reiterated a “sector perform” rating and set a C$26.00 price objective on shares of Valeant Pharmaceuticals Intl in a research report on Tuesday, May 23rd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a research report on Thursday, June 29th. Finally, TD Securities boosted their price objective on Valeant Pharmaceuticals Intl to C$26.00 and gave the stock a “hold” rating in a research report on Wednesday, July 12th.
In other news, Director Schutter Richard Urbain De bought 4,900 shares of the business’s stock in a transaction on Monday, August 21st. The stock was purchased at an average cost of C$14.35 per share, for a total transaction of C$70,315.00. Also, Director John Paulson sold 24,700 shares of the company’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of C$14.66, for a total value of C$362,102.00.
Shares of Valeant Pharmaceuticals Intl (TSE VRX) opened at 16.52 on Friday. Valeant Pharmaceuticals Intl has a 12-month low of $11.20 and a 12-month high of $37.70. The stock has a 50 day moving average price of $18.61 and a 200 day moving average price of $17.34. The firm’s market capitalization is $5.76 billion.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.